Problems of process and problems of outcome regarding drugs: historical evolution of their definitions
DOI:
https://doi.org/10.17533/udea.rfnsp.9494Keywords:
medication errors, drug therapy, drug utilization, treatment outcome, adverse effects, patientsAbstract
Objective: to analyze the historical evolution of the concepts of Drug-Related Problems (DRP), Drugrelated utilization problems (DRUP) and negative clinical outcomes (NCO) in order to unify the terminology at the national and international level, since confusion has been observed regarding the definitions of problems of process (causes) and problems of outcome (effects). Such issue may interfere with and have a negative impact on therapeutic goals. Methodology: a narrative literature review using the Medline and SciELO electronic databases in order to obtain information including the following concepts and terms: drp, drup, nco. No restrictions by date of publication were set, and the search was carried out in Spanish and English. Results: no consensus regarding the terms used with drug-related problems was found in the documents. In Decree 2200/2005 (Colombia), DRP are problems of drug use and negative outcomes of medication. Likewise, NCO are the negative clinical outcomes of medication (effects), and the DRUP are the problems in drug usage (DRP preventable causes associated with medication errors). Conclusions: although there are a number of terms for defining drugrelated problems, there is no national or international consensus on them.
Downloads
References
(1). Organización Mundial de la Salud. 10 datos sobre seguridad del paciente. Ginebra: OMS; 2011
(2). Ministerio de la Protección Social. Guía técnica buenas prácticas para la seguridad del paciente en la atención en salud [internet]2010[acceso 8 de junio de 2011]. Disponible en: http://mps.minproteccionsocial.gov.co/newsogc/comite/User/Library/Folders/Comite8/NT%20Nov%202009.pdf.
(3). Ministerio de la Protección Social. Lineamientos para la implementación de la Política de Seguridad del Paciente [internet] Bogotá: El Ministerio; 2008 [acceso 8 de junio de 2011]. Disponible en: http://201.234.78.38/ocs/public/seg_paciente/Default.aspx.
(4). Organización Mundial de la Salud. Uso racional de medicamentos: progresos realizados en la aplicación de la estrategia farmacéutica de la OMS. Ginebra: OMS; 2006.
(5). Organización Mundial de la Salud. La farmacovigilancia: garantía de seguridad en el uso de los medicamentos. Ginebra: OMS, 2004.
(6). Farcas A, Sinpetrean A, Mogosan C, Palage M, Vostinaru O, Bojita Metal. Adverse drugre actions detected by stimulated spontaneous reporting in an internal medicine departmentin Romania. Eur J Intern Med 2010; 2(5):453-457. DOI: https://doi.org/10.1016/j.ejim.2010.05.014
(7). WuT Y, Jen MH, Bottle A, Molokhia M, Aylin P, Bell D, etal.Ten-year trends in hospital admissions for adverse drugreactions in England 1999-2009. J R Soc Med 2010; 103(6):239-250. DOI: https://doi.org/10.1258/jrsm.2010.100113
(8). Smithells RW. Defects and disabilities of thalidomide children. Br MedJ 1973; 1(5848):269-272. DOI: https://doi.org/10.1136/bmj.1.5848.269
(9). Staunton H. Valproate, spinabifida, and birth defect registries. Lancet1989; 1(8634):381. DOI: https://doi.org/10.1016/S0140-6736(89)91751-0
(10). Alsdorf R, Wyszynski DF. Teratogenicity of sodium valproate. Expert Opin Drug Saf 2005; 4(2):345-353. DOI: https://doi.org/10.1517/14740338.4.2.345
(11). Sánchez AR, Rogers RS, Sheridan PJ. Tetracycline and other tetracycline-derivative stainingoftheteethandoralcavity.IntJ Dermatol 2004; 43(10):709-715. DOI: https://doi.org/10.1111/j.1365-4632.2004.02108.x
(12). Hepler C, Strand L. Oportunities and responsibilities in pharmaceutical care.Am J. Hosp Pharm 1990; 47:533-543. DOI: https://doi.org/10.1093/ajhp/47.3.533
(13). Organización Mundial de la Salud. Promoción del uso racional de medicamentos: componentes centrales. Ginebra:OMS; 2002.
(14). Amariles P, Giraldo N, Gómez A. Gestión y aseguramiento de la calidad de la farmacoterapia: aproximación para el contexto del Sistema de Salud de Colombia. Medellín: Grupo de Promoción y Prevención Farmacéutica. 2007.
(15). Amariles P, Martínez F, Faus MJ. Atención Farmacéutica: conceptos, procesos y casos prácticos. Madrid: Ergon; 2007. 210 p.
(16). Abu Ruz SM, Bulatova NR , Yousef AM. Validation of comprehensive classification tool for treatment-related problems. Pharm World Sci 2006; 28: 222-232. DOI: https://doi.org/10.1007/s11096-006-9048-0
(17). Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. Drug Intell Clin Pharm 1990; 24: 1093-1097.
(18). Fernandez-Llimos F, Faus MJ, Gastelurrutia MA, Baena MI, Martinez Martinez F. Evolución del concepto deproblemas relacionados con medicamentos: resultados como el centro del nuevo paradigma. Seguimiento Farmacoterapéutico 2005; 3(4): 167-188.
(19). CipolleRJ,StrandLM,MorleyPC. Pharmaceuticalcarepractice.NuevaYork: McGraw-Hill; 1998.
(20). Panel de Consenso ad hoc. Consenso sobre problemas relacionados con
medicamentos. Granada. Pharm Care Esp 1999;1:107-112.
(21). GarcíaP. Conocimiento del paciente sobre sus medicamentos. [tesis doctoral].Granada: Universidad de Granada, Facultad de Farmacia; 2008.
(22). American Society of Hospital Pharmacists. ASHP guide lines on a standardized method for pharmaceutical care. Am J Health Syst Pharm 1996; 53(14): 1713-1716. DOI: https://doi.org/10.1093/ajhp/53.14.1713
(23). American Society of Hospital Pharmacists. ASHP guide line on out sourcing pharmaceutical services. Am J Health SystPharm1998;55(15):1611-1617 DOI: https://doi.org/10.1093/ajhp/55.15.1611
(24). Pérez C. Problemas de salud relacionados con los medicamentos (PRM) con motivo de ingreso hospitalario [tesis doctoral]. Madrid: Universidad Complutense de Madrid; 2010.
(25). Panel de Consenso adhoc. Segundo Consenso de Granada sobre Problemas Relacionados con Medicamentos. ArsPharmaceutica 2002;43: 175-184.
(26). Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. DICP. 1990 Nov;24(11):1093-7. DOI: https://doi.org/10.1177/106002809002401114
(27). Schaefer M. Discussing basic principles for acoding system of drug-related problems: the case of PI-doc.PharmWorldSci2002;24(4):120-127.
(28). WONCAClassification Committee. Aninternational glossaryfor general/family practice. Fam Pract 1995; 12: 341-369. DOI: https://doi.org/10.1093/fampra/12.3.341
(29). Dona bedian A.Evaluating the quality of medical care.MilbankMemFund Q, 1966; 44(3): 166-206. DOI: https://doi.org/10.2307/3348969
(30). FarrisKB,KirkingDM.Assessing the quality of pharmaceutical care.II.Applicationofconceptsofqualityassess ment from medical care.Ann Pharmacother 1993; 27(2): 215-223. DOI: https://doi.org/10.1177/106002809302700218
(31). GouvelaWA,BungayKM,MassaroFJ,WareJE,Jr.Paradigmfor the management of outcomes.Am J Hosp Pharm 1999; 48: 1912-1916.
(32). Kozma CM, Reeder CE, Schulz RM. Economic,clinicalandhu-manisticoutcomes:aplanningmodelforpharmacoeconomicre-search. ClinTher 1993; 15(6): 1121-1132.
(33). Espejo J, Fernández-Llimós F, Machuca M, FausMJ.Problemas relacionados con medicamentos: definición y propuestadeinclu-siónenlaClasificaciónInternacionaldeAtenciónPrimaria(CIAP) de la WONCA. Pharm Care Esp 2002; 4(2): 122-127.
(34). García-Jiménez E. Incumplimiento como causa de problema relacionado con medicamentos en el seguimiento farmacoterapéutico. [tesis doctoral]. Granada: Universidad de Granada, Facultad de Farmacia; 2003.
(35). Foro de Atención Farmacéutica. Documento sobre PRMy RNM:conceptosy definiciones.Farmacéuticos 2006; 315: 2-29.
(36). Comité de Consenso. Tercer Consenso de Granada sobre Proble-masRelacionados con los Medicamentos (PRM) y Resultados NegativosasociadosalaMedicación(RNM).Ars.Pharm2007;48:5-17.
(37). Ministerio de Protección Social y Organización Panamericanade la Salud.Política Farmacéutica Nacional.Bogotá:elMinisterio;2003.
(38). AmarilesP. Seguimiento farmacéutico de pacientes en el contexto del sistema de salud de Colombia. Revista Nuevos Tiempos 2002;10(2): 93-113.
(39). Agudelo N, Cifuentes J, Amariles P. Impacto de la intervención del químico farmacéutico en el proceso de atención ambulatoria en una institución de salud en Medellín, Colombia. Pharm Care Esp 2003; 5: 1-12.
(40). Amariles P, Giraldo N. Método Dáder de seguimiento farmacoterapéutico a pacientes y problemas relacionados con la utilización de medicamentos en el contexto de Colombia. Pharmacy Practice. 2003;1(3): 99-104.
(41). Colombia. Decreto Número 2200 del 2005, por el cual se reglamenta el servicio farmacéutico y se dictanotras disposiciones. Bogotá: Ministerio de la Protección Social; 2005.
(42). AmarilesP. Terminology for problems related to druguse. AmJ Health Syst Pharm. 2006; 63(7): 616-617. DOI: https://doi.org/10.2146/ajhp050504
(43). Fernandez-LlimosF,FausMJ.From―Drug-relatedproblems‖to―negativeclinicaloutcomes‖.AmJHealth-SystPharm2005;62:2348-2350.340 DOI: https://doi.org/10.2146/ajhp050358
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Andrea Salazar Ospina, Dora M. Benjumea, Pedro Amariles M.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The contents of the articles are the responsibility of the authors
The editorial committee has editorial independence from the National School of Public Health "Héctor Abad Gómez" of the University of Antioquia.
The editorial committee is not responsible for aspects related to copying, plagiarism or fraud that may appear in the articles published in it.
When you are going to reproduce and disclose photographs or personal data in printed or digital format, informed consent is required. Therefore, this requirement is required of the author at the time of receipt of the manuscript.
Authors are responsible for obtaining the necessary permissions to reproduce any material protected by reproduction rights.
The authors preserve the moral rights and assign the economic rights that will correspond to the University of Antioquia, to publish it, distribute electronic copies, include them in indexing services, directories or national and international databases in Open Access, under the Creative Commons Attribution license -Not Commercial-Share Equal 4.0 International Commercial (CC BY-NC-SA) which allows others to distribute, remix, retouch, and create from the work in a non-commercial way, as long as the respective credit and license are granted. new creations under the same conditions.
The authors will sign the declaration of transfer of economic rights to the University of Antioquia, after the acceptance of the manuscript.
The editorial committee reserves the right to reject the articles whose authors do not offer satisfactory explanations about the contribution of each author, to meet the criteria of authorship in the submission letter. All authors must meet the four criteria of authorship according to ICMJE: "a) .- That there is a substantial contribution to the conception or design of the article or to the acquisition, analysis or interpretation of the data. b) That they have participated in the design of the research work or in the critical review of its intellectual content. c) .- That has been intervened in the approval of the final version that will be published.d). That they have the capacity to respond to all aspects of the article in order to ensure that issues related to the accuracy or integrity of any part of the work are adequately investigated and resolved. "
-- 
--
